Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 10
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Profound Medical Corp
PROF
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$6.90
-0.01
-0.14%
Dern. MÀJ: Oct 9, 7:42 PM
$6.88
-0.0299
-0.43%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Profound Medical Financials
Profound Medical (PROF) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Profound Medical Sees Q3 Sales $9.800M-$10.000M vs $6.934M Est
Profound Medical (NASDAQ:PROF) sees Q3 sales of $9.800 million-$10.000 million vs $6.934 million analyst estimate.
Benzinga Newsdesk
PRO
Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
Benzinga Newsdesk
PRO
Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
Benzinga Newsdesk
PRO
Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same period last year. The
Benzinga Newsdesk
PRO
Profound Medical Sees FY2026 Sales $25.000M
Profound Medical (CSE2: PRN) sees FY2026 sales of $25.000 million.
Benzinga Newsdesk
PRO
Profound Medical Q1 EPS $(0.19) Beats $(0.35) Estimate, Sales $5.337M Miss $6.648M Estimate
Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 47.22 percent increase over losses of $(0.36) per share from the
Benzinga Newsdesk
